Effective Antimicrobial StewaRdship StrategIES (ARIES)
ARIES
1 other identifier
interventional
1,257
1 country
1
Brief Summary
Background Prospective review and feedback (PRF) of antibiotic prescriptions is a labor-intensive core strategy of antimicrobial stewardship (AMS). The investigators hypothesized that a computerized decision support system (CDSS) providing recommendations for antibiotics, investigations and referrals would reduce the requirement for PRF without causing harm. Methods A parallel-group, 1:1 block-cluster randomized, cross-over study was conducted in 32 medical and surgical wards from March to August 2017. The intervention arm comprised voluntary use of CDSS at first prescription of piperacillin-tazobactam or a carbapenem, while the control arm was compulsory CDSS. PRF was continued for both arms. Primary outcome was 30-day mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2018
CompletedFirst Submitted
Initial submission to the registry
July 1, 2019
CompletedFirst Posted
Study publicly available on registry
July 8, 2019
CompletedNovember 14, 2019
November 1, 2019
7 months
July 1, 2019
November 12, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
30-day mortality
Death at 30 days
Follow-up up to 30 days from the start date of the first episode of piperacillin-tazobactam or carbapenem use
Secondary Outcomes (9)
7-day clinical response
Follow-up up to 7 days from the date of the first episode of piperacillin-tazobactam or carbapenem use
30-day re-infection
Re-start of piperacilin-tazobactam or carbapenem 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
30-day readmission
Readmissions 30 days after the cessation of first episode of piperacillin-tazobactam or carbapenem use
length of stay
It is assessed from the date of admission till the date of discharge or up to 6 months
6-months incidence of multi-drug resistant organisms
up to 6 months (Clinical cultures only)
- +4 more secondary outcomes
Study Arms (2)
Voluntary CDSS
EXPERIMENTALVoluntary use of computerized decision support with prospective review and feedback
Compulsory CDSS
NO INTERVENTIONCompulsory use of computerized decision support with prospective review and feedback
Interventions
Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
Eligibility Criteria
You may qualify if:
- Patients who are started on the 1st episode of piperacillin-tazobactam or carbapenem during the study period.
- Medical and surgical wards
You may not qualify if:
- Intensive care unit (ICU), high dependency and step-down care wards
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tan Tock Seng Hospital
Singapore, 308433, Singapore
Related Publications (8)
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.
PMID: 27080992BACKGROUNDDavey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.
PMID: 28178770BACKGROUNDLew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, Ang B, Lye D, Teng CB. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2015 Apr;70(4):1219-25. doi: 10.1093/jac/dku479. Epub 2014 Dec 3.
PMID: 25473028BACKGROUNDSchuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, van der Linden PD, Natsch S, Hertogh CMPM, Wolfs TFW, Schouten JA, Kullberg BJ, Prins JM. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Jul;16(7):847-856. doi: 10.1016/S1473-3099(16)00065-7. Epub 2016 Mar 3.
PMID: 26947617BACKGROUNDYong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother. 2010 May;65(5):1062-9. doi: 10.1093/jac/dkq058. Epub 2010 Mar 9.
PMID: 20215130BACKGROUNDThursky K. Use of computerized decision support systems to improve antibiotic prescribing. Expert Rev Anti Infect Ther. 2006 Jun;4(3):491-507. doi: 10.1586/14787210.4.3.491.
PMID: 16771625BACKGROUNDLeibovici L, Kariv G, Paul M. Long-term survival in patients included in a randomized controlled trial of TREAT, a decision support system for antibiotic treatment. J Antimicrob Chemother. 2013 Nov;68(11):2664-6. doi: 10.1093/jac/dkt222. Epub 2013 Jun 5.
PMID: 23743088BACKGROUNDChow AL, Lye DC, Arah OA. Mortality Benefits of Antibiotic Computerised Decision Support System: Modifying Effects of Age. Sci Rep. 2015 Nov 30;5:17346. doi: 10.1038/srep17346.
PMID: 26617195BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- A parallel-group, 1:1 block-cluster randomized, cross-over study
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2019
First Posted
July 8, 2019
Study Start
March 1, 2017
Primary Completion
September 30, 2017
Study Completion
February 28, 2018
Last Updated
November 14, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will share
Anonymized data can be made available only after project agreement is made